Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Quantitative imaging using radiomics can capture distinct phenotypic differences between tumors and may have predictive power for certain phenotypes according to specific genetic mutations. We aimed to identify the clinicoradiologic predictors of tumors with ALK (anaplastic lymphoma kinase), ROS1 (c-ros oncogene 1), or RET (rearranged during transfection) fusions in patients with lung adenocarcinoma.A total of 539 pathologically confirmed lung adenocarcinomas were included in this retrospective study. The baseline clinicopathologic characteristics were retrieved from the patients' medical records and the ALK/ROS1/RET fusion status was reviewed. Quantitative computed tomography (CT) and positron emission tomography imaging characteristics were evaluated using a radiomics approach. Significant features for the fusion-positive tumor prediction model were extracted from all of the clinicoradiologic features, and were used to calculate diagnostic performance for predicting 3 fusions' positivity. The clinicoradiologic features were compared between ALK versus ROS1/RET fusion-positive tumors to identify the clinicoradiologic similarity between the 2 groups.The fusion-positive tumor prediction model was a combination of younger age, advanced tumor stage, solid tumor on CT, higher values for SUV(max) and tumor mass, lower values for kurtosis and inverse variance on 3-voxel distance than those of fusion-negative tumors (sensitivity and specificity, 0.73 and 0.70, respectively). ALK fusion-positive tumors were significantly different in tumor stage, central location, SUV(max), homogeneity on 1-, 2-, and 3-voxel distances, and sum mean on 2-voxel distance compared with ROS1/RET fusion-positive tumors.ALK/ROS1/RET fusion-positive lung adenocarcinomas possess certain clinical and imaging features that enable good discrimination of fusion-positive from fusion-negative lung adenocarcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Self-citationDecoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Aerts, H. J. W. L., Velazquez, E. R., Leijenaar, R. T. H., Parmar, C., Grossmann, P., Carvalho, S., Bussink, J., Monshouwer, R., Haibe-Kains, B., Rietveld, D., et al. (2014) · Nature Communications · doi:10.1038/ncomms5006 · Cited by 5,132
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Radiomics: the process and the challenges
Kumar, V., Gu, Y., Basu, S., Berglund, A., Eschrich, S. A., Schabath, M. B., Forster, K., Aerts, H. J. W. L., Dekker, A., Fenstermacher, D., et al. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2012.06.010 · Cited by 2,258 · cited 1×
“number of automatically extracted data-characterization algorithms.(30,31) The present study found significant radiomics-based predictors for fusion-positive tumors.”
MethodCrizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Cited by
Machine and deep learning methods for radiomics
Avanzo, M., Wei, L., Stancanello, J., Vallières, M., Rao, A., Morin, O., Mattonen, S. A., & El Naqa, I. (2020) · Medical Physics · doi:10.1002/mp.13678 · Cited by 605
Beyond imaging: The promise of radiomics
Avanzo, M., Stancanello, J., & El Naqa, I. (2017) · Physica Medica · doi:10.1016/j.ejmp.2017.05.071 · Cited by 483
Characterization of PET/CT images using texture analysis: the past, the present… any future?
Hatt, M., Tixier, F., Pierce, L., Kinahan, P. E., Le Rest, C. C., & Visvikis, D. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3427-0 · Cited by 475
Radiomics and radiogenomics in lung cancer: A review for the clinician
Thawani, R., McLane, M., Beig, N., Ghose, S., Prasanna, P., Velcheti, V., & Madabhushi, A. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.10.015 · Cited by 450
Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer
Rios Velazquez, E., Parmar, C., Liu, Y., Coroller, T. P., Cruz, G., Stringfield, O., Ye, Z., Makrigiorgos, M., Fennessy, F., Mak, R. H., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0122 · Cited by 391
Metadata
- Authors
- Yoon, H. J., Sohn, I., Cho, J. H., Lee, H. Y., Kim, J.-H., Choi, Y.-L., Kim, H., Lee, G., Lee, K. S., & Kim, J.
- Venue
- Medicine
- Published
- 2015-10
- Volume
- 94
- Issue
- 41
- Pages
- e1753
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2313906428
- Cited by
- 120
- References
- 6
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach. https://app.cochat.ai/papers/10.1097/md.0000000000001753
- The paper
- Yoon, H. J., Sohn, I., Cho, J. H., Lee, H. Y., Kim, J.-H., Choi, Y.-L., Kim, H., Lee, G., Lee, K. S., & Kim, J. (2015). Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach. Medicine. https://doi.org/10.1097/md.0000000000001753
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.